SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits

Core Insights - Sight Sciences (SGHT) published a systematic literature review and meta-analysis in the European Journal of Ophthalmology, confirming the long-term safety and efficacy of the OMNI Surgical System (OMNI) for patients with primary open-angle glaucoma [1][4][9] Company Performance - Following the announcement, SGHT's shares increased by 7.9%, closing at $3.69, with a year-to-date gain of 1.4% compared to the industry's decline of 11.4% [3] - SGHT currently has a market capitalization of $179.1 million and projects an earnings growth of 17.7% for the next year [5] Clinical Evidence - The meta-analysis covered 29 publications across 22 unique studies involving 2,379 eyes, demonstrating that OMNI provides sustained reductions in intraocular pressure (IOP) and medication use while maintaining a favorable safety profile [9] - Nearly 89% of patients achieved at least a 20% reduction in IOP at 6, 12, and 24 months, with approximately 66–68% remaining medication-free at 6 and 12 months [10] Economic Value - The cost-utility analysis indicated that patients treated with OMNI achieved an average of 8.95 quality-adjusted life years (QALYs) over a lifetime horizon, slightly higher than the 8.93 QALYs for the leading market alternative, iStent inject [11]